CR11737A - Polipéptidos modificados del factor ix y usos de los mismos - Google Patents

Polipéptidos modificados del factor ix y usos de los mismos

Info

Publication number
CR11737A
CR11737A CR11737A CR11737A CR11737A CR 11737 A CR11737 A CR 11737A CR 11737 A CR11737 A CR 11737A CR 11737 A CR11737 A CR 11737A CR 11737 A CR11737 A CR 11737A
Authority
CR
Costa Rica
Prior art keywords
factor
modified
polypeptides
polipeptides
same
Prior art date
Application number
CR11737A
Other languages
English (en)
Inventor
Alan Brooks
John E Murphy
Marian Seto
Xiaoqiao Jian
Chandra Patel
Uwe Gritzan
Kornelia Kirchner
Ulrich Haupts
Original Assignee
Bayer Schering Pharma Ag
Bayer Healthcare Llc
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Bayer Healthcare Llc, Schering Corp filed Critical Bayer Schering Pharma Ag
Publication of CR11737A publication Critical patent/CR11737A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se divulgan polipéptidos modificados del factor IX, tales como los polipéptidos del factor IX con uno o más sitios de glicosilación introducidos. Los polipéptidos modificados del factor IX pueden exhibir un incremento de la estabilidad in vitro o in vivo, tal como una semivida plasmática más prolongada. Asimismo se divulgan procedimientos de fabricar polipéptidos modificados del factor IX y a procedimientos de usar modificados del factor IX para, por ejemplo, tratar a pacientes afectados por hemofilia B.
CR11737A 2008-04-16 2010-10-15 Polipéptidos modificados del factor ix y usos de los mismos CR11737A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12456708P 2008-04-16 2008-04-16
US4596108P 2008-04-17 2008-04-17

Publications (1)

Publication Number Publication Date
CR11737A true CR11737A (es) 2011-02-07

Family

ID=41265284

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11737A CR11737A (es) 2008-04-16 2010-10-15 Polipéptidos modificados del factor ix y usos de los mismos

Country Status (17)

Country Link
EP (1) EP2288622A4 (es)
JP (1) JP2011517951A (es)
KR (1) KR20110005862A (es)
CN (1) CN102083856A (es)
AU (1) AU2009244633A1 (es)
BR (1) BRPI0910702A2 (es)
CA (1) CA2721683A1 (es)
CO (1) CO6311000A2 (es)
CR (1) CR11737A (es)
DO (1) DOP2010000311A (es)
EC (1) ECSP10010551A (es)
IL (1) IL208718A0 (es)
MX (1) MX2010011345A (es)
RU (1) RU2010146387A (es)
SG (1) SG189790A1 (es)
SV (1) SV2010003704A (es)
WO (1) WO2009137254A2 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383388B2 (en) * 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
CN102026653B (zh) * 2007-10-15 2014-06-18 北卡罗来纳-查佩尔山大学 半衰期延长的人因子ⅸ变体
FI3581650T3 (fi) * 2008-09-15 2023-03-23 Uniqure Biopharma B V IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
KR20230156435A (ko) 2010-07-09 2023-11-14 바이오버라티브 테라퓨틱스 인크. 인자 iｘ 폴리펩티드 및 이들의 사용 방법
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
AU2013204511B2 (en) * 2010-11-03 2016-03-17 Gc Biopharma Corp. Modified factor ix polypeptides and uses thereof
HUE043894T2 (hu) 2011-06-10 2019-09-30 Bioverativ Therapeutics Inc Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
EP2842966B1 (en) 2012-04-27 2018-08-15 Nihon University Therapeutic agent for epithelial and endothelial injury
EP2877202A4 (en) 2012-07-25 2016-06-01 Biogen Ma Inc BLOOD FACTORY MONITOR TEST AND USES THEREOF
EP3542861A1 (en) 2012-09-25 2019-09-25 Bioverativ Therapeutics Inc. Methods of using fix polypeptides
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
US10370431B2 (en) 2013-02-15 2019-08-06 Bioverativ Therapeutics Inc. Optimized factor VIII gene
AR095527A1 (es) 2013-03-15 2015-10-21 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix
WO2015048330A2 (en) 2013-09-25 2015-04-02 Biogen Idec Ma Inc. On-column viral inactivation methods
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
JP2017500017A (ja) 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
TWI700101B (zh) 2014-03-24 2020-08-01 美商百歐維拉提夫治療公司 凍乾之因子ｉｘ調配物
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
EP3411478B1 (en) 2016-02-01 2022-06-08 Bioverativ Therapeutics Inc. Optimized factor viii genes
CN105695616A (zh) * 2016-04-22 2016-06-22 王冬国 诊断甲状腺癌的分析标志物及其应用
KR20260008164A (ko) 2016-12-02 2026-01-15 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
JP2020505424A (ja) 2017-01-31 2020-02-20 バイオベラティブ セラピューティクス インコーポレイテッド 因子ｉｘ融合タンパク質ならびにその製造および使用方法
FR3069540B1 (fr) 2017-07-28 2019-09-13 Universite Claude Bernard Lyon 1 Proteine modifiee avec demi-vie amelioree
JP7374883B2 (ja) 2017-08-09 2023-11-07 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子およびその使用
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
CA3077380A1 (en) 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
KR20210005608A (ko) 2018-04-04 2021-01-14 시질론 테라퓨틱스, 인크. 이식 가능한 입자 및 관련 방법
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
MA52630B1 (fr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Procédés de traitement de l'hémophilie a
CA3108799A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
JP2022531095A (ja) 2019-04-17 2022-07-06 コディアック バイオサイエンシーズ， インコーポレイテッド エキソソーム及びａａｖの組成物
JP7803014B2 (ja) 2019-09-30 2026-01-21 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
IL299333A (en) 2020-06-24 2023-02-01 Bioverativ Therapeutics Inc Methods for the purification of viral vectors
WO2022182869A1 (en) 2021-02-24 2022-09-01 Bluehalo Llc System and method for a digitally beamformed phased array feed
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
WO1999003496A1 (en) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US20040254106A1 (en) * 2001-09-04 2004-12-16 Carr Francis J. Modified factor ix
WO2004091487A2 (en) * 2003-04-09 2004-10-28 Wyeth Hemophilia treatment by inhalation of coagulation factors
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
CA2549413A1 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated factor ix
US8383388B2 (en) * 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
RU2010146387A (ru) 2012-05-27
AU2009244633A1 (en) 2009-11-12
EP2288622A4 (en) 2012-04-18
ECSP10010551A (es) 2010-11-30
DOP2010000311A (es) 2011-02-28
SV2010003704A (es) 2011-02-21
BRPI0910702A2 (pt) 2016-07-05
EP2288622A2 (en) 2011-03-02
CO6311000A2 (es) 2011-08-22
MX2010011345A (es) 2011-02-23
CN102083856A (zh) 2011-06-01
CA2721683A1 (en) 2009-11-12
SG189790A1 (en) 2013-05-31
JP2011517951A (ja) 2011-06-23
KR20110005862A (ko) 2011-01-19
IL208718A0 (en) 2010-12-30
WO2009137254A2 (en) 2009-11-12
WO2009137254A3 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
CR11737A (es) Polipéptidos modificados del factor ix y usos de los mismos
ECSP12011637A (es) Polipéptidos del factor ix modificados y usos de los mismos
MX382693B (es) Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.
DOP2016000042A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
CO6331368A2 (es) Factores modificados de polipeptidos vii (fvii)
ECSP12011908A (es) OCTAHIDROPIRROLO[3,4-c]PIRROLOS DISUSTITUIDOS COMO
MX356958B (es) Análogos de péptido-2 tipo glucagón (glp-2).
BRPI0920914A8 (pt) Perácidos alfa-ceto e métodos para produzir e usar os mesmos.
SV2009003393A (es) Polipeptidos de factor vii modificaciones y usos de los mismos
CR20140512A (es) Dispositivos y metodos para la fabricación de aditivos de componentes de implante
AR084057A1 (es) Composiciones para el cuidado de telas
IN2014DN06191A (es)
IN2014DN06104A (es)
CR20110630A (es) Compuestos carboxamida y su uso como inhibidores de calpaína
UY35703A (es) Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
DOP2010000251A (es) Paramyxovirus eficaz como antitumoral
UY32445A (es) Composicion y procedimiento para usar aminopiridinas
PA8796001A1 (es) Moduladores tieno- y furo-pirimidina del receptor de histamina h4
MX2012001409A (es) Fragmento de agrina modificado capaz de restaurar la potencia muscular para utilizarse como un medicamento.
BR112014016803A2 (pt) amidas macrocíclicas como inibidoras de protease
UY29361A1 (es) Pirroles e imidazoles sustituídos, composiciones que los contienen, procedimiento de fabricación y utilización
CR11457A (es) Composiciones farmaceuticas que contienen antagonistas de bradykinin y acido hialuronico y los usos de los mismos
UY32975A (es) Derivados de aminopiridina
ECSP13012613A (es) Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)